The cost of hepatitis C treatment may decrease in Russia

The Federal Antimonopoly Service (FAS) has agreed on prices for domestic analogues of hepatitis C drugs and is working on the issue of their legalization and launch into circulation. This may happen after the government issues a permit for the sale and production of generics. This was told to Izvestia by the press service of the antimonopoly authority.

Tread marks: there is a shortage of an unparalleled drug for cancer patients in the Russian Federation

How long will the mesna reserves last and when will the country have its own production?

"The service has agreed on prices for the domestic drug Velpatasof under the international nonproprietary name (INN) Velpatasvir+Sofosbuvir." They have been reduced by 40% relative to the registered price for the foreign reference of Epcluse," the FAS said.

They also noted that the price for a package of this domestic generic of 28 tablets in a dosage of 100 mg + 400 mg is agreed at 68.7 thousand rubles, and the price of the original drug in the same volume is 114.5 thousand.

In addition, the FAS reported that the service had agreed on the cost of the first domestic generic drug Pigleria within the framework of the INN Glecaprevir + Pibrentasvir. Prices have also been reduced relative to the registered price of the foreign reference drug Maviret by 40%. The cost of packaging this drug from 84 tablets in a dosage of 100 mg + 40 mg is agreed at the level of 103 thousand rubles. And for the same packaging of the original medicine, you will now have to pay 171.7 thousand rubles.

Read more in the exclusive Izvestia article:

They will take into account: the cost of treatment for hepatitis C may be reduced in the Russian Federation